General information:
Substance group: direct oral anticoagulance (DOAK) / selective thrombin inhibitor ATC: B01AE07
Trade name: Pradaxa®
dosing available: hard capsules 75 / 110 / 150 mg
Reference ranges:
For the prophylaxis of strokes and systemic embolisms in non-valvular atrial fibrillation:
2x150mg
Cmax (2h after ingestion): 175 ng/mL (117-275 ng/mL)
Trough level (before the next intake): 91 ng/mL (61-143 ng/mL)
To treat deep vein thrombosis and pulmonary embolisms and for the prevention of relapsing deeper vein thrombosis and pulmonary embolism:
2x150mg
Trough level (before the next intake): 60 ng/mL (39-95 ng/mL)
For the prophylaxis of venous thromboembolism after elective hip or knee replacement surgery:
1x220mg
Cmax (2h after ingestion): 71 ng/mL (35-162 ng/mL)
Trough level (before the next intake): 22 ng/mL (13-36 ng/mL)
1x150mg
Trough level (before the next intake): 48 ng/mL (30-72 ng/mL)
Toxic dose : not established yet
Sampling:
Material: Citrate Plasma (Monovette Green) Minimum volume for analysis: 500µl
Recommendation: trough level (directly before the next intake)
Request (internal): … Requirement (external): after consultation (+49 221 478 5066)
Analytics:
Test principle: liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS)
Protein precipitation with acetonitrile, chromatographic separation, mass spectrometry
Analysis according to mass charge ratio
Analysis system: triple stage Quadrupol mass spectrometer (LC-MS/MS)
Findings release: on the same working day, via LIMS
DrugBank: https://go.drugbank.com/drugs/DB14726